Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. We currently track 1 Biotech story that mention Post-exposure prophylaxis, all published on September 12, 2026.
Last mentioned: 1h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. We currently track 1 Biotech story that mention Post-exposure prophylaxis, all published on September 12, 2026. Each carries 4 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Post-exposure prophylaxis. Shared-story counts are live from our verified record — not editorial picks.
Biotech and pharma stakeholders see CDC data showing a 17% rise in rabies exposure inquiries translating into 33% higher vaccine utilization and 76% higher HRIG utilization. The trend signals demand pressure for post-exposure prophylaxis biologics.
Source: wjbo.iheart.com · kogo.iheart.com
Post-exposure prophylaxis is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
